Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer – a systematic review and network meta-analysis of survival data

References

• Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47:S2–S6.
   PubMed Web of Science ®Google Scholar
• Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology. 2013;266(2):407–430.
   PubMed Web of Science ®Google Scholar
• Pan YX, Fu YZ, Hu DD, et al. Stereotactic body radiotherapy vs. Radiofrequency ablation in the treatment of hepatocellular carcinoma: a Meta-Analysis. Front Oncol. 2020;10:1639.
   PubMed Web of Science ®Google Scholar
• Jackson WC, Tao Y, Mendiratta-Lala M, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys. 2018;100(4):950–958.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Tamburini E, Iñarrairaegui M, et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a Meta-analysis of randomized trials. Onco Targets Ther. 2018;11:7315–7321.
   PubMed Web of Science ®Google Scholar
• Eriguchi T, Takeda A, Tateishi Y, et al. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: systematic review and Meta-analysis of propensity score studies. Hepatol Res. 2021;51(7):813–822.
   PubMed Web of Science ®Google Scholar
• Ren N, Xue J, Qin S, et al. Comparison of transarterial y90 radioembolization and conventional transarterial chemoembolization in hepatocarcinoma patients: a Meta-analysis. pharmaceutical-sciences. 2020;82(s6):76–81.
   Google Scholar
• Wang Y, Zeng L, Chen W, et al. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a Meta-analysis. Hepatol Res. 2016;46(1):58–71.
   PubMed Web of Science ®Google Scholar
• White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network Meta-analysis: model estimation using multivariate Meta-regression. Res Synth Methods. 2012;3(2):111–125.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Syn Meth. 2021;12(1):55–61.
   PubMed Web of Science ®Google Scholar
• Akinwande O, Philips P, Scoggins C, et al. Radioembolization versus chemoembolization (DEBDOX) for the treatment of unresectable hepatocellular carcinoma: a propensity matched study. Anticancer Res. 2016;36:239–246.
   PubMed Web of Science ®Google Scholar
• Berger NG, Tanious MN, Hammad AY, et al. External radiation or ablation for solitary hepatocellular carcinoma: a survival analysis of the SEER database. J Surg Oncol. 2017;116(3):307–312.
   PubMed Web of Science ®Google Scholar
• Bettinger D, Gkika E, Schultheiss M, et al. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. BMC Cancer. 2018;18(1):807.
   PubMed Web of Science ®Google Scholar
• Bush DA, Smith JC, Slater JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: Results of an interim analysis. Int J Radiat Oncol Biol Phys. 2016;95(1):477–482.
   PubMed Web of Science ®Google Scholar
• Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299(14):1669–1677.
   PubMed Web of Science ®Google Scholar
• Chu HH, Kim JH, Yoon HK, et al. Chemoembolization combined with radiofrequency ablation for Medium-Sized hepatocellular carcinoma: a Propensity-Score analysis. J Vasc Interv Radiol. 2019;30(10):1533–1543.
   PubMed Web of Science ®Google Scholar
• Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology. 2019;69:2533–2545.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Huang YH, Chiou YY, et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the milan criteria: a propensity score analysis. Liver Transpl. 2011;17(5):556–566.
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Chiba T, Ooka Y, et al. Transarterial chemoembolization as a substitute to radiofrequency ablation for treating barcelona clinic liver cancer stage 0/a hepatocellular carcinoma. Oncotarget. 2018;9(30):21560–21568.
   PubMedGoogle Scholar
• Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in asian patients with hepatocellular carcinoma. J Hepatol. 2020;73(1):121–129.
   PubMed Web of Science ®Google Scholar
• Kim N, Kim HJ, Won JY, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81–87.
   PubMed Web of Science ®Google Scholar
• Kim TH, Koh YH, Kim BH, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2021;74(3):603–612.
   PubMed Web of Science ®Google Scholar
• Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715–1721.
   PubMed Web of Science ®Google Scholar
• Liu PH, Lee YH, Hsu CY, et al. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the milan criteria. Ann Surg Oncol. 2014;21(12):3835–3843.
   PubMed Web of Science ®Google Scholar
• Pan Y-X, Fu Y-Z, Hu D-D, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective propensity score matching study. Cancers. 2019;11(8):1116.
   PubMed Web of Science ®Google Scholar
• Parikh ND, Marshall VD, Green M, et al. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: an analysis of SEER-medicare. J Med Imaging Radiat Oncol. 2018;62(5):673–681.
   PubMed Web of Science ®Google Scholar
• Pitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015;38(2):352–360.
   PubMed Web of Science ®Google Scholar
• Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: Analysis of the national cancer database. J Clin Oncol. 2018;36(6):600–608.
   PubMed Web of Science ®Google Scholar
• Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–1163.e2.
   PubMed Web of Science ®Google Scholar
• Shen PC, Chang WC, Lo CH, et al. Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable Medium-Sized hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2019;105(2):307–318.
   PubMed Web of Science ®Google Scholar
• Su T-S, Qu S, Chen L, et al. Stereotactic body radiation therapy vs. Transarterial chemoembolization in inoperable barcelona clinic liver cancer stage a hepatocellular carcinoma: a retrospective, Propensity-Matched analysis. Front Oncol. 2020;10:347.
   PubMed Web of Science ®Google Scholar
• Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–459.
   PubMed Web of Science ®Google Scholar
• Wang G, Shen W, Song M, et al. Results of combined treatment with transcatheter hepatic arterial chemoembolization and whole-liver irradiation with the moving strip technique in unresectable hepatocellular carcinoma. Int J Clin Oncol. 2000;5(6):380–385.
   Google Scholar
• Yun B-Y, Lee HW, Kim SU, et al. Prognosis of early-stage hepatocellular carcinoma: Comparison between trans-arterial chemoembolization and radiofrequency ablation. Cancers. 2020;12(9):2527–2511.
   Web of Science ®Google Scholar
• Elshaarawy O, Gomaa A, Omar H, et al. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma. 2019;6:105–117.
   PubMed Web of Science ®Google Scholar
• Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and Meta-analysis of observational studies. Radiother Oncol. 2019;131:135–144.
   PubMed Web of Science ®Google Scholar
• Comito T, Clerici E, Tozzi A, et al. Liver metastases and SBRT: a new paradigm? Rep Pract Oncol Radiother. 2015;20(6):464–471.
   PubMedGoogle Scholar
• Hasan S, Abel S, Verma V, et al. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation. J Gastrointest Oncol. 2019;10(5):999–1009.
   PubMed Web of Science ®Google Scholar
• Sanford NN, Pursley J, Noe B, et al. Protons versus photons for unresectable hepatocellular carcinoma: Liver decompensation and overall survival. Int J Radiat Oncol Biol Phys. 2019;105(1):64–72.
   PubMed Web of Science ®Google Scholar